OR WAIT null SECS
© 2022 MJH Life Sciences and Psychiatric Times. All rights reserved.
© 2022 MJH Life Sciences™ and Psychiatric Times. All rights reserved.
January 21, 2022
Put treatment resistance in perspective with Sheldon H. Preskorn, MD.
December 26, 2021
Psychiatric Times featured a wide variety of psychiatric issues in this year’s CMEs.
December 21, 2021
Caplyta is now FDA-approved for depressive episodes from bipolar I and II.
December 08, 2021
The importance of specifically defining a drug’s mechanism as partial agonism or antagonism/partial agonism for better clinical outcomes.
November 01, 2021
Some psychiatric medications that can trigger Torsades de Pointes (TdP), a potentially fatal polymorphic ventricular tachycardia that arises during abnormal ventricular repolarization. Are you aware of the risk factors that increase risk of TdP?
October 30, 2021
Microdosing at “Tranquillum House,” and its implications for real-world experimental psychopharmacology.
October 22, 2021
Results suggest that psilocybin therapy may prove to be helpful in improving quality of life for patients with cancer.
October 21, 2021
What is the real-world clinical efficacy of SSRIs and other antidepressant medications compared to RCT placebos?
October 20, 2021
New Drug Application to be submitted for MDD in late 2022, with separate filing for PPD planned for early 2023.
October 07, 2021
The history of medicine is a never-ending work in progress. What is the next chapter in the psychiatry and genetics story?